Biohaven Ltd. (BHVN)
| Market Cap | 1.48B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -780.11M |
| Shares Out | 132.69M |
| EPS (ttm) | -7.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,260,582 |
| Open | 9.67 |
| Previous Close | 10.81 |
| Day's Range | 9.52 - 11.21 |
| 52-Week Range | 7.48 - 44.28 |
| Beta | 3.59 |
| Analysts | Buy |
| Price Target | 29.79 (+167.18%) |
| Earnings Date | Nov 10, 2025 |
About BHVN
Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment o... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price target is $29.79, which is an increase of 167.18% from the latest price.
News
US Stocks Mixed; Biohaven Shares Fall
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.1% on Friday.
Cautiously Bullish After Biohaven's Cash Runway And Dilution Risk Rise
BHVN's investment case definitely weakened after Opakalim's Phase 2 MDD miss. This also means they'll discontinue their psychiatric development. BHVN's pipeline remains diverse, but key assets like Op...
Biohaven Misses The Mark In Depression Trial, Stock Falls
On Wednesday, Biohaven Ltd. (NYSE: BHVN) reported results from a Phase 2 proof-of-concept study evaluating BHV-7000 for major depressive disorder (MDD).
Biohaven's depression drug fails mid-stage trial, shares fall
Biohaven said on Wednesday its experimental depression drug did not meet the main goal of a mid-stage trial, adding to a string of trial and regulatory setbacks for the drugmaker this year.
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
In a pretreated population of participants with advanced/metastatic cancer and the majority with prior PD-(L)1 treatment, BHV-1510 2.5 mg/kg Q3W plus cemiplimab resulted in confirmed objective respons...
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Q3 Earnings: Falling Back To Earth With A Thud
Biohaven (BHVN) narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending and steep share price declines. BHVN's pipeline includes Opakalim for depr...
FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Wednesday.
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Announces Proposed Public Offering of Common Shares
NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd.
Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection
Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.
Biohaven shares plunge after US FDA declines to approve brain disorder drug
Shares of Biohaven fell more than 40% on Wednesday after the U.S. Food and Drug Administration declined to approve its experimental treatment for a rare brain disorder.
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare genetic...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit – BHVN
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biohaven To Contact Him Directly To Discuss Their Options If you purchased or acquire...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Biohaven To Contact Him Directly To Discuss Their Options
Biohaven: Despite Troriluzole Program Delay, FDA Review On Track For Q4 2025
Biohaven's troriluzole shows 50%-70% slowing of SCA disease progression, with FDA review now on track for Q4 2025 after a brief delay. FDA is no longer requiring an advisory committee meeting to revie...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Biohaven To Contact Him Directly To Discuss Their Options If you purchased or acquire...
Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2025, totaled approximately $408.2 million VYGLXIA NDA for spinocerebellar ataxia (SCA) PDUFA date 4Q2025, completed cl...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit - BHVN
NEW YORK , Aug. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).
Law Offices of Frank R. Cruz Encourages Biohaven Ltd.
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Biohaven Ltd. (BHVN) Investors To Inquire About Securities Fraud Class Action.
Law Offices of Howard G. Smith Encourages Biohaven Ltd.
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Biohaven Ltd. (“Biohaven” or the “Company”) (NY...